Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

VNRX Relative to the S&P 500

VNRX Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the VolitionRX Ltd. (AMEX:VNRX) seasonal charts above shows that a Buy Date of August 12 and a Sell Date of November 20 has resulted in a geometric average return of 28.2% above the benchmark rate of the S&P 500 Total Return Index over the past 17 years. This seasonal timeframe has shown positive results compared to the benchmark in 12 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 17 years by an average of 35.78% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

To download VNRX seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: VNRX